Lapatinib (EGFR and HER2 tyrosine kinase inhibitor (TKI)), gefitinib (EGFR TKI), ZD4054 or BQ-123 (ETAR antagonist), GM6001 (matrix metalloprotease inhibitor), PP-2 (Src inhibitor) or Tiron (superoxide scavenger) all inhibited the increase in EGFR and HER2 transactivation induced by the addition of ET-1 to NSCLC cells [65]. Here, EGFR is linked to non-small cell lung carcinoma.